The Effects of Ziprasidone 320 mg on Glucose and Plasma Lipids in Patients With Diabetes Type II and Schizophrenia or Schizoaffective Disorder.
Phase of Trial: Phase II/III
Latest Information Update: 28 Jul 2011
At a glance
- Drugs Ziprasidone (Primary)
- Indications Schizoaffective disorder; Schizophrenia
- Focus Pharmacodynamics
- 28 Jul 2011 Actual initiaion date changed from Jun 2008 to Jan 2010 as reported by ClinicalTrials.gov.
- 28 Jul 2011 Actual initiaion date changed from Sep 2001 to Sep 2003 as reported by ClinicalTrials.gov.
- 06 Aug 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.